A phase II study of systemic chemotherapy with S-1 and Oxaliplatin followed by gastrectomy with D2 or D2 plus limited para-aortic lymph node dissection in HER2 negative advanced gastric or esophagogastric junction cancer with extensive lymph node metastasis - A phase II study of systemic chemotherapy with S-1 and Oxaliplatin followed by gastrectomy with D2 or D2 plus limited para-aortic lymph node dissection in HER2 negative advanced gastric or esophagogastric junction cancer with extensive lymph node metastasis

Cancer Institute Hospital0 sites35 target enrollmentJuly 1, 2017

Overview

No summary available.

Registry

who.int

Start Date

July 1, 2017

End Date

September 28, 2027

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Cancer Institute Hospital

•1\) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ or mucosal cancer 2\) Women during pregnancy or breast\-feeding 3\) Severe mental disease 4\) Under treatment with systemic steroid 5\) HBs antigen positive 6\) Under treatment with flucytosine, phenytoin, or warfarin 7\) Allergy to iodine 8\) History of hypersensitivity to oxaliplatin or S\-1 9\) Peripheral motor neuropathy or peripheral sensory neuropathy by any reason 10\) Edema of limbs or trunk by any reason 11\) Interstitial pneumonia, pulmonary fibrosis or severe emphysema. 12\) Active bacterial or fungal infection 13\) Past history of myocardial infarction or unstable angina pectoris within 6 months 14\) Uncontrollable hypertension 15\) Uncontrollable diabetes mellitus or routine administration of insulin